Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, women's health and dermatology products maker Warner Chilcott (NASDAQ:WCRX) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Warner Chilcott's business and see what CAPS investors are saying about the stock right now.

Warner Chilcott facts

Headquarters (Founded)

Rockaway, N.J. (1968)

Market Cap

$5.45 Billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$971.2 Million

Management

CEO Roger Boissonneault (Since 2005)

CFO Paul Herendeen (Since 2005)

Return on Equity (Average, Past Three Years)

(0.8%)

4-Month Return

112%

Competitors

Wyeth (NYSE:WYE)

Johnson & Johnson (NYSE:JNJ)

CAPS Members Bearish on WCRX Also Bearish on

Cisco Systems (NASDAQ:CSCO)

Vale (NYSE:VALE)

CAPS Members Bullish on WCRX Also Bullish on

Palm (NASDAQ:PALM)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 18 of the 105 members who have rated Warner Chilcott -- some 17% -- believe the stock will underperform the S&P 500 going forward. These bears include All-Stars TSIF and greenwave3, both of whom are ranked in the top 4% of our community.

Two days ago, TSIF chimed in on Warner Chilott's big $3.1 billion buy of Procter & Gamble's (NYSE:PG) drug business:

All of the large pharmaceuticals have been plagued with trying to keep a fresh stable of drugs from which they can extract a premium as sole source. Warner may be underestimating that part of the game, and underestimating the debt load service they now have. While they gain additional markets and this is a chance for them to break out of their current low margin shell, it's unlikely the deal was worth the steep rise and a new high for Warner's stock today.

In a pitch from the same day, greenwave3 echoes that sentiment:

I can't imagine how Moody's affirmed [Warner Chilcott's] credit ratings to complete the PG Pharma purchase. They borrowed the entire amount to finance the deal, and it increased the company's debt from $800 million to $3.9 billion. I understand that the acquisition is "accretive," but they are on the clock to deliver new products when their existing patents expire in a few short years. [Warner Chilcott] is going to be busy servicing debt for a long time, and somewhere in their budget they better plan to do the R&D necessary to take their business forward. I would estimate that they've bitten off more than they can safely chew.

What do you think about Warner Chilcott, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson and Procter & Gamble are Motley Fool Income Investor picks. The Fool owns shares of Procter & Gamble. The Fool's disclosure policy always gets a perfect score.